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ABSTRACT
Background: Obstructive sleep apnoea (OSA) has been
reported as a predictor of left ventricle (LV) diastolic
dysfunction and left atrium (LA) remodelling. The aim of
this study is to evaluate the impact of OSA treatment
with a continuous positive airway pressure device (CPAP)
on the LA volume and function, as well as on the LV
diastolic function.
Methods: In total, 56 OSA patients were studied. All
patients underwent real-time three-dimensional (RT3DE)
and two-dimensional echocardiogram with tissue Doppler
evaluation in order to estimate LA volumes, function and
LV diastolic performance. A total of 30 patients with an
apnoea-hypopnoea index greater than 20 were randomly
selected to receive sham CPAP (n=15) or effective
CPAP (n=15) for 24 weeks. They underwent echo
examination on three different occasions: at baseline,
after 12 weeks and 24 weeks of CPAP or sham CPAP.
Results: In the effective CPAP group we observed the
following changes from the baseline to the 24-week echo
evaluation: (a) a reduction in the E/E9 ratio (10.3 (1.9) to
7.9 (1.3), p=0.03); (b) an increase in the LA passive
emptying fraction (28.8% (11.9%) to 46.8% (9.3%),
p=0.01); and (c) a reduction in the LA active emptying
fraction (42.7% (11.5%) to 25.7 (15.7), p,0.01). In the
sham group, there were no changes from the baseline to
the 24-week echo. We found a positive correlation
between 24 week/baseline LA active emptying volume
and 24 week/baseline E/E9 ratios (r=0.40, p,0.05) and
a negative correlation between 24 week/baseline LA
passive emptying volume and 24 week/baseline E/E9
ratios (r=20.53, p,0.05). No significant changes were
found on LA total emptying fraction.
Conclusion: CPAP improved LV diastolic function and LA
passive emptying, but not LA structural variables in OSA
patients.
Trial registration number: NCT00768807.
Obstructive sleep apnoea (OSA) is a prevalent
condition in the general population, and it is
characterised by recurrent upper airway obstruc-
tion during sleep, which results in periods of
apnoea/hypopnoea, oxyhaemoglobin desaturation,
abnormal nocturnal arousals and daytime sleepi-
ness.
1 It is also described as an important factor of
increasing cardiovascular morbidity and mortality.
Several studies have linked OSA to increased risk of
stroke, hypertension and death.
2 Notwithstanding,
the majority of risk factors for OSA, such as
obesity, male gender and ageing, are also related to
cardiovascular disorders, which makes it difficult
to define OSA as an independent risk factor.
3
Studies have reported a higher frequency of
diastolic dysfunction in OSA patients when
compared to controls.
4 The reduction of left
ventricle (LV) compliance might result in left
atrium (LA) overstretching and dilation in order
to maintain proper LV filling. Diastolic dysfunc-
tion and LA enlargement have been associated
with several clinical conditions, including hyper-
tension, diabetes, left ventricular systolic dysfunc-
tion, obesity and ageing.
56In addition, according
to epidemiological studies, LA enlargement is an
independent predictor of major cardiovascular
events.
7
The association between OSA and LA volume
augmentation has been previously studied and
seems to be related to OSA severity. Diastolic
dysfunction is also likely to be attached to LA
functional and structural remodelling.
89However,
the impact of the effective OSA treatment with
long-term continuous positive airway pressure on
LA function and structure has never been analysed
using real-time three-dimensional echocardio-
graphy (RT3DE).
We hypothesised that the morphological and
functional LA changes that occur in patients with
OSA could be at least partially reversed after the
effective OSA treatment with a chronic continuous
positive airway pressure device (CPAP). Therefore,
we sought to evaluate the LA volume and function,
as well as LV diastolic variables, in moderate to
severe OSA patients before and after 24 weeks of
effective or sham CPAP.
METHODS
Population
A total of 56 recently diagnosed patients with mild
to severe, untreated OSA (29–70 years, 29 men)
were recruited and referred to the sleep laboratory
of the Universidade Federal de Sao Paulo (Sao
Paulo, Brazil). OSA diagnoses were confirmed by
full polysomnography. All patients were first
examined by a member of the cardiology staff,
and blood pressure was recorded by the ausculta-
tory method. Hypertension was considered accord-
ing to the seventh report of the Joint National
Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure.
10
Individuals were excluded from both groups on
the basis of the following characteristics: body
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2, history of coronary artery disease
and atrial fibrillation, cardiomyopathy and poor-quality ima-
ging on two-dimensional echocardiography and/or RT3DE.
Other medical conditions, such as severe arrhythmias and
pulmonary and valvular heart disease were also excluded.
The research protocol was approved by the institution’s
ethics committee, and informed consent was obtained from
each patient.
Polysomnography
Each patient underwent polysomnographic recording, with a
minimum duration of 7 hours. Recordings were performed
using 16-channel Somnologica Studio Science, (Medcare,
Iceland) with a resolution of 200 Hz on two different occasions:
(1) baseline polysomnography (before entry) and (2) CPAP
titration polysomnography. Two researchers visually scored the
recordings according to standard criteria.
11 12
The variables analysed were total sleep time, sleep efficiency
(sleep time/recording time 6100), sleep latency (time from
lights-off to sleep onset), REM and non-REM sleep percentage,
apnoea-hypopnoea index (apnoea + hypopnoea events per
hour), arousals/hour and oxygen saturation. Apnoea was
defined as a decrease in airflow of at least 80% for 10 seconds
or more, and hypopnoea was defined as a decrease in airflow of
at least 50% for 10 seconds or more. An apnoea-hypopnoea
index (AHI) .5 was considered diagnostic for OSA.
Study design and CPAP randomisation
This is a randomised, double-blinded, placebo-controlled, single-
centre study, in which a subsample of 30 patients, selected from
the initial general group (n=56), with AHI .20 were randomly
divided to receive placebo (sham CPAP) (n=15) or effective
CPAP for 24 weeks (n=15). The randomisation of patients
with AHI .20 was based on the American Academy of Sleep
Medicine recommendation for CPAP treatment.
13 (fig 1).
Sham CPAP consisted of a modified traditional CPAP,
Resmed S8. Modifications were performed on both the
equipment and the mask. A swivel including four small holes,
comprising a 12-mm
2 area, was incorporated into the mask close
to the tracheal connection. In addition, a specially manufac-
tured silicone cork with a 3.5-mm orifice was inserted in the
pressured air output of the CPAP machine. These modifications
were aimed at losing pressure, but allowed the sensation of
circulating air into the mask. All sham CPAPs were regulated at
10 cm H2O and delivered a maximum of 1.5 cm H2O of positive
pressure, as measured with a vacuum manometer. They were all
tested, and end-tidal CO2 was assessed in the mask, which was
within 35–45 mm Hg during the entire polysomnography
titration night for all patients.
12 Patients were followed every
2 weeks by the medical staff, and compliance and side effects of
CPAP were systematically checked. Compliance was considered
a minimal usage of 5 hours nightly, as determined by the hour
meter. All 15 patients allocated to the sham group received
effective CPAP treatment after completion of the protocol.
Echocardiography
All individuals were submitted to a baseline comprehensive 2D
echocardiographic study according to the American Society of
Echocardiography guidelines, followed by a RT3DE examina-
tion performed by two experienced investigators who were
blinded to the polysomnographic results. The randomised
patients underwent echo examination on three different
occasions: at baseline, after 12 weeks, and after 24 weeks of
CPAP treatment or placebo (sham CPAP). A commercially
available machine (IE33, Philips Medical Systems, Andover, MA,
USA) with digital storage software for offline analysis was
used.
14
RD3DE was performed with an X3 matrix-array transducer
(1–3 MHz) for acquisition of ‘‘full-volume’’ real-time pyramidal
volumetric data sets along four consecutive cardiac cycles.
Individuals were instructed to hold their breath, and images
were coupled with electrocardiographic recordings. Apical two-
chamber and four-chamber views were extracted from the
pyramidal data set during expiration. Both left ventricular and
LA cavities were included in the pyramidal scan volume. The
RT3DE data sets were digitally stored and analysed using
analysis software (QLab-Philips version 4.2; Philips Medical
systems). Maximum LA volume, minimum LA volume and LA
volume before contraction were obtained.
Anatomical landmarks used to calculate LA volumes were
manually identified as follows: lateral, septal, anterior and
posterior points of the mitral annulus and the higher point of
the LA roof. Points determined to represent the pulmonary vein
ostia or LA appendages were excluded from the measurement.
The LA internal endocardial border of each frame was defined
by automated processing and manually adjusted for pulmonary
vein ostia and LA appendage exclusion. From these data, a three-
dimensional model of LA volume was generated.
Figure 1 Study design. AHI, apnoea-
hypopnoea index; OSA, obstructive sleep
apnoea; CPAP, continuous positive
airway pressure device.
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emptying fraction, the difference between maximal volume
and the minimum volume divided by the maximum volume; (2)
active emptying volume, the difference between the volume
before atrial contraction and the minimum volume; (3) active
emptying fraction, active emptying volume divided by the
volume before atrial contraction; (4) passive emptying volume,
the difference between maximal volume and the volume before
atrial contraction; and (5) passive emptying fraction, the passive
emptying volume divided by the maximum volume.
15–17
The LV ejection fraction was also assessed by RT3DE via
evaluation of apical four-chamber and two-chamber views using
the pyramidal three-dimensional data set.
18 Left ventricular
diastolic function was assessed with Doppler echocardiography
in accordance with the American and European Societies of
Echocardiography recommendations.
19 20 The mitral inflow was
recorded with the pulsed-wave Doppler sample volume located
between the leaflet tips. The following variables were measured:
peak flow velocity in early diastole (E wave), peak velocity at
atrial contraction (A wave) and mitral deceleration time. Tissue
Doppler imaging of the mitral annulus (maximal diastolic early
E9 and late A9 waves derived from averaged velocities of lateral
and septal curves). These data were used for calculating the E/E9
ratio. The LV mass index was obtained according to American
Society of Echocardiography recommendations, which are based
on two-dimensional echocardiographic linear measurements.
21
Statistical analysis
Data are presented as mean (SD) or frequencies. One-way
ANOVA was used to compare the OSA mild, moderate and
severe subgroups with respect to the following parameters:
RT3DE, Doppler, polysomnography and demographic variables.
Repeated measures ANOVA was used to compare the rando-
mised individuals before and after 12 weeks and 24 weeks of
effective CPAP and sham CPAP. The Bonferroni post-hoc test
was applied to assess significant differences after CPAP
treatment. x
2 was chosen to compare the frequencies of
categorical data. The level of significance was set at p,0.05.
Pearson matrices were used to estimate the correlations
between the 24-week/baseline LA active and passive emptying
volumes ratios with 24-week/baseline E/E9 ratio.
Table 1 Clinical characteristics and polysomnographic results
Mild OSA
(n=17)
Moderate OSA
(n=18)
Severe OSA
(n=21)
Age (years) 49.8 (10.8) 53.1 (10.4) 56.8 (9.30)
Male gender (%) 47.1 44.4 61.9*{
Body mass index (kg/m
2) 28.4 (7.3) 29.2 (5.7) 30.3 (6.2)
Neck circumference (cm) 36.6 (4.1) 37.2 (3.8) 38.8 (3.9)
Hypertension (%) 29.5 33.3 66.7*{
Systolic blood pressure (mm Hg) 140.1 (20.3) 134.5 (18.1) 142.1 (19.5)
Diastolic blood pressure (mm Hg) 88.8 (12.9) 80.7 (11.8) 86.8 (12.7)
Diabetes mellitus (%) 0 0 19.9*{
Heart rate (beats/min) 67.0 (13.4) 60.4 (10.4) 65.3 (9.4)
Sleep efficiency (%) 86.6 (7.5) 79.7 (13.4) 83.5 (12.0)
Total sleep time (min) 362.7 (95.6) 353.8 (71.8) 362.8 (83.2)
Stage 1 (%) 7.8 (10.6) 7.3 (7.3) 6.7 (11.8)
Stage 2 (%) 55.6 (13.6) 46.0 (21.5) 57.7 (18.6)
Slow wave sleep (%) 18.3 (10.1) 27.9 (14.0) 24.8 (16.3)
Rapid eye movement sleep (%) 19.0 (7.6) 20.9 (13.7) 15.4 (10.5)
Apnoea-hypopnoea index (events/h) 9.9 (2.6) 21.1 (3.7)* 54.8 (22.5)*{
Microarousal index/h 12.9 (6.50) 16.6 (6.6)* 25.2 (13.7)*{
O2 saturation nadir (%) 87 (3.8) 83.1 (10) 76.1 (0.2)*
*Different from mild, p,0.05; {different from moderate, p,0.05.
Table 2 Echocardiogram baseline results
Mild OSA
(n=17)
Moderate OSA
(n=18)
Severe OSA
(n=21)
Left ventricular mass index (g/m
2) 83.4 (20.0) 83.6 (12.2) 94.0 (27.0)
E velocity (cm/s) 73.8 (17.8) 74.4 (18.9) 68.1 (14.6)
A velocity (cm/s) 64.6 (14.1) 71.2 (19.3) 74.3 (19.5)
E/A ratio 1.2 (0.4) 1.1 (0.3) 1.0 (0.3)
E mitral deceleration time (ms) 189.2 (34.5) 231.8 (45.2) 247.6 (48.2)*
E/E9 ratio 9.7 (1.9) 10.4 (3.1) 11.6 (3.6)*
Averaged E9 velocity (cm/s) 7.7 (1.5) 7.3 (2.0) 6.2 (1.8)*{
Averaged A9 velocity (cm/s) 6.1 (1.4) 6.8 (1.7) 8.2 (1.9)*{
E9/A9 ratio 1.3 (0.4) 1.1 (0.3) 0.8 (0.3)*{
S velocity (cm/s) 7.4 (2.1) 8.1 (2.5) 7.6 (1.7)
3D LA maximum volume (ml) 37.1 (14.7) 40.8 (8.9) 57.6 (31.0)*{
3D LA minimum volume (ml) 13.9 (5.5) 16.6 (4.0) 24.5 (20.9)*{
3D volume before LA contraction (ml) 24.3 (10.2) 24.7 (5.4) 44.2 (28.4)*{
*Different from mild, p,0.05; {different from moderate, p,0.05.
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General and polysomnographic results
In total60 OSA patients were initiallyinvitedtoparticipateinthis
study and 56 were included. One was excluded because of angina
symptoms, a second because of abnormal lung function, and the
last two because of poor quality imaging on RT3DE. All
randomised patients (n=30) successfully completed the 24 weeks
of CPAP or sham CPAP. Full compliance failed in two patients
who belonged to the sham group because of non-complicated
upper airway infection. They refrained from device usage for a
mean of 5 days. Their data were included in the final sample.
Higher frequency of male gender, diabetes and hypertension
was found in the severe compared to mild and moderate OSA
groups (p,0.05). Mean age, body mass index, neck circumfer-
ence, heart rate and systolic and diastolic blood pressure did not
differ between groups. As expected, the apnoea-hypopnoea
index (events/h), microarousal index/h, and O2 saturation nadir
were significantly different between all groups (p,0.05).
Baseline characteristics and polysomnographic data are
displayed in table 1.
Echocardiographic baseline results
In the initial sample of 56 OSA patients, the severe OSA group
showed higher values of E mitral deceleration time and E/E9
ratio compared to the mild OSA group and higher average A9
velocity, 3D maximum, minimum and pre-contraction LA
volumes compared to the moderate and mild groups. (p,0.05,
all). Also, the severe group presented lower E9 and E9/A9 ratios
than the mild and moderate groups.
CPAP versus sham results
Out of 30 OSA patients who underwent polysomnography for
CPAP titration, only 15 who were randomised to the effective
CPAP group had successful positive pressure titration, as
observed by correction of AHI, oxygen saturation and snoring.
A minimal of 5 hours/night of CPAP usage was ensured in
both groups, according to hour-meter analysis, with the
exception of two patients in the sham group.
We did not observe any significant differences between the
sham CPAP and effective CPAP groups where the baseline
demographic and echocardiographic variables were concerned as
displayed in table 3.
However, when baseline echo variables were compared to the
12-week and 24-week evaluation of both treatments, we
observed only in the CPAP effective treatment group: (a) an
increase in the E9/A9 ratio (1.0 (0.4) to 1.5 (0.7), p=0.02); (b) a
reduction in the E/E9 ratio (10.3 (1.9) to 7.9 (1.3), p=0.03); (c)
an increase in the E9 averaged mean velocity (7.0 cm/s (1.5) to
9.5 cm/s (1.9), p,0.01); (d) an increase in the LA passive
emptying volume (13.2 ml (6.1) to 21.0 ml (7.4), p=0.04); (e)
an increase in the LA passive emptying fraction (28.8% (11.9%)
to 46.8% (9.3%), p=0.01); (f) a reduction in the LA active
emptying volume (14.0 ml (6.5) to 6.3 ml (4.3), p=0.05); and
(g) a reduction in the LA emptying ejection fraction (42.7%
(11.5%) to 25.7% (15.7%), p,0.01) (fig 2). There were no
significant differences after 12 weeks of CPAP or during the
entire sham usage in respect to these variables.
Additionally, there was a trend towards a reduction of the E/
A ratio from baseline to 24-week echo evaluation in the effective
CPAP group (1.0 (0.2) to 1.4 (0.1), p=0.06).
Table 3 Effective continuous positive airway pressure (CPAP) treatment and sham groups baseline
characteristics
Effective CPAP
(n=15)
Sham
(n=15) p Value
Age (years) 56.0 (10.1) 53.1 (10.4) 0.9
Male gender (%) 60.0 46.0 0.4
Body mass index (kg/m
2) 29.6 (6.2) 30.8 (6.2) 0.6
Neck circumference (cm) 37.9 (4.5) 38.2 (3.5) 0.8
Hypertension (%, n) 53.0 (8) 53.0 (8) 1
Systolic blood pressure (mm Hg) 142.3 (19.8) 138.1 (10.5) 0.5
Diastolic blood pressure (mm Hg) 87.2 (12.1) 81.8 (8.2) 0.2
Diabetes mellitus (%, n) 13.0 (2) 13.0 (2) 1
Heart rate (beats/min) 67.8 (13.4) 68.9 (12.5) 0.8
Sleep efficiency (%) 83.8 (7.5) 86.2 (12.1) 0.5
Total sleep time (min) 358.1 (104.5) 385.2 (49.6) 0.4
Apnoea-hypopnoea index (events/h) 39.2 (21.3) 43.9 (20.1) 0.5
Microarousal index/h 18.9 (9.7) 20.4 (9.6) 0.7
O2 saturation nadir (%) 77.4 (18.3) 79.2 (10.4) 0.8
Left ventricular mass index (g/m
2) 82.5 (17.6) 85.6 (14.7) 0.6
E velocity (cm/s) 70.7 (13.2) 60.6 (25.2) 0.6
A velocity (cm/s) 69.9 (15.8) 75.1 (21.1) 0.5
E/A ratio 1.0 (0.2) 1.0 (0.4) 0.6
E mitral deceleration time (ms) 227.0 (38.8) 244.2 (21.3) 0.1
E/E9 ratio 10.3 (1.9) 10.5 (2.6) 0.8
Averaged E9 velocity (cm/s) 7.0 (1.5) 6.6 (1.9) 0.6
Averaged A9 velocity (cm/s) 7.8 (2.3) 7.1 (1.6) 0.3
E9/A9 ratio 1.0 (0.4) 1.0 (0.3) 0.9
S velocity (cm/s) 8.2 (1.9) 7.8 (2.3) 0.5
3D LA maximum volume (ml) 45.2 (11.9) 46.2 (17.3) 0.9
3D LA minimum volume (ml) 18.0 (5.1) 18.6 (6.4) 0.8
3D volume before LA contraction (ml) 32.1 (9.5) 30.8 (13.6) 0.8
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Heart 2009;95:1872–1878. doi:10.1136/hrt.2009.173625 1875Figure 2 Left atrial (LA) function and left ventricular diastolic performance throughout 24 weeks of sham or effective continuous positive airway
pressure (CPAP) treatment.
Figure 3 (A) Correlation between 24-week/baseline left atrium (LA) active emptying volume and 24-week/baseline E/E9 ratios. (B) Correlation
between 24-week/baseline left atrium (LA) passive emptying volume and 24-week/baseline E/E9 ratios.
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throughout the 24-week CPAP therapy between the baseline
and 24-week echo evaluation (82.5 g/m
2 (17.6 vs 86.7 g/m
2
(18.5, NS). Other echocardiographic variables and clinical data
such as LV ejection fraction, LA maximal, minimum and pre-
contraction fundamental volumes, body mass index, blood
pressure and heart rate did not significantly change in both
effective CPAP and sham groups, at any time.
Pearson matrices showed a positive correlation between 24-
week/baseline LA active emptying volume and 24-week/base-
line E/E9ratios (r=0.40, p,0.05) and a negative correlation
between 24-week/baseline LA passive emptying volume and 24-
week/baseline E/E9 ratios (r=20.53, p,0.05) (fig 3).
DISCUSSION
The main finding of this study is the significant enhancement of
LA passive function, as noticed by the increment of LA passive
emptying and reduction of LA active function after 24 weeks of
CPAP treatment. This finding seems to be directly associated
with the improvement of LV diastolic function after the
effective treatment of OSA. To the best of our knowledge, this
is the first study which analyses the effects of CPAP on the LA
dynamics and LV diastolic function using RT3DE and tissue
Doppler technologies. In addition, the randomised placebo-
controlled intervention group with similar demographic vari-
ables, supports the idea that OSA contributes significantly to
left atrial dysfunction
The association of LV diastolic impairment and OSA has been
studied, but has not yet been fully explained. The possible
explanations are constant catecholaminergic hyperactivity, a
rise in the negative intrathoracic pressure and many conditions
highly prevailing in OSA, such as hypertension, obesity and
ageing, which act in synergy to result in LV diastolic burden and
myocardial relaxation impairment.
22 23 We observed impaired
diastolic function in the severe OSA group compared to mild
and moderate OSA groups, when analysing the E/E9 and E9/A9
ratios. The poor diastolic function in OSA patients is in
agreement with the study of Arias et al, which used pulse
Doppler.
24
Alterations in LA volumes and function could be linked to
diastolic impairment in patients with OSA. A reduced passive
LA emptying results in a less significant motion of the mitral
valve annulus, which can be shown by the reduced velocity of
the E9 wave. The impairment of LA passive emptying also
contributes to a larger residual LA volume before its active
contraction. According to the landmark Frank-Starling study,
there is an augmentation of LA contraction force due to LA pre-
systolic volume and fibre length increase. The atrial contraction
becomes of crucial importance during LV filling, as suggested by
the higher values of 3D LA active emptying volume and 3D LA
active emptying fraction in the severe OSA group. These
findings are in accordance with the increased velocity of A9 in
that group. In our opinion, the constant atrial overload
ultimately plays an important part in the augmentation of
maximum LA volume in OSA patients.
25 26
The partial improvement of diastolic function after long-term
treatment with CPAP supports a physiopathological association
between diastolic function and OSA. Some non-controlled
studies using different criteria for selection have found changes
in diastolic variables after CPAP.
27 28 The CPAP would lead to a
reduction in the exaggerated negative intrathoracic pressure,
which, in turn, would lead to a reduction in apnoeic-hypopnoeic
events and, therefore, in the ventricular afterload.
29
The reduction in the active LA emptying and the increase in
the LA passive emptying (fig 2) reflect the observed changes in
LV relaxation dynamics. This finding is reinforced by a
significant linear positive correlation between 24-week/baseline
LA active emptying volume and 24-week/baseline E/E9 ratios
and by the negative correlation between 24-week/baseline LA
passive emptying volume and 24-week/baseline E/E9 ratios
(fig 3).
Although we did not observe significant differences in
absolute LA volumes between baseline and 24-week echo
examination in the CPAP group, LA passive emptying volume
and passive emptying fraction increased. On the other hand, LA
active emptying volume and LA active emptying fraction
significantly increased after CPAP. This finding reveals an atrial
functional remodelling which could anticipate a LA structural
modification.
In addition, another potential novelty of this study is the
concept that the relation between LA active and passive
emptying, as assessed by RT3DE, could be a sensitive indicator
for LA work and reflects the severity of LV diastolic function.
Precision in the estimate of LA size is necessary for clinical
practice owing to the association between increased LA volume
and major adverse cardiovascular outcomes. LA analysis using
RT3DE has been validated as a prognostic mark of major cardiac
events, and shows potential in terms of accuracy, practicability
and reproducibility.
15 16 This technology has already been used
to study LA structure in patients with OSA, and OSA severity
was shown to be an independent predictor of LA maximal
enlargement.
8
In summary, our results do not simply highlight the impact of
OSA treatment on diastolic function, as seen in previous studies
which used pulse-Doppler technology, but also reveal the effect
of CPAP on the LA functional performance in this population.
The repercussion of a longer CPAP therapy on LA structure and
absolute volumes, as well as its potential impact on the
development or recurrence of atrial rhythm disturbances, need
to be investigated further.
Study limitations
The main potential limitation was the presence of hypertension
in this population and its influence on diastolic function. We
may not have found a significant decrease in blood pressure,
probably because we recorded it on a by-office basis instead of
by 24-hour ambulatory blood pressure monitoring. In fact, our
purpose was to study the ultimate effect of CPAP on LA
function in a commonplace OSA population, with its typical
comorbidities. Moreover, a previous study showed that OSA
severity is an independent predictor of LA functional and
structural remodelling when corrected for hypertension, BMI,
gender and diabetes.
8
CONCLUSIONS
We demonstrated, using RT3DE, that the functional LA burden
observed in OSA could be, at least partially, reversed after
effective long-term CPAP therapy. This finding seems to be
strongly associated with the improvement of diastolic function
in this population after correction for apnoeic-hypopnoeic
events.
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